

1 **Full Title: Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273**  
2 **Boost after Prime with Ad26.COVS.2 among Healthcare Workers in South Africa: the**  
3 **single-arm, open-label, Phase 3 SHERPA Study**

5 **Short Title: Safety and Effectiveness of mRNA-1273 Boost after AD26.COVS.2 Prime**

7 **Authors:** Nigel Garrett<sup>1,2</sup>, Tarylee Reddy<sup>3</sup>, Nonhlanhla Yende-Zuma<sup>3</sup>, Azwidhi Takalani<sup>4</sup>,  
8 Kubashni Woeber<sup>5</sup>, Annie Bodenstein<sup>6</sup>, Phumeza Jonas<sup>6</sup>, Imke Engelbrecht<sup>6</sup>, Waasila  
9 Jassat<sup>7</sup>, Harry Moultrie<sup>7</sup>, Debbie Bradshaw<sup>8</sup>, Ishen Seocharan<sup>3</sup>, Jackline Odhiambo<sup>4</sup>, Kentse  
10 Khuto<sup>4</sup>, Simone I. Richardson<sup>9,10</sup>, Millicent A. Omondi<sup>11</sup>, Rofhiwa Nesamari<sup>11</sup>, Roanne S.  
11 Keeton<sup>11</sup>, Catherine Riou<sup>11,12</sup>, Thandeka Moyo-Gwete<sup>9,10</sup>, Craig Innes<sup>13</sup>, Zwelethu Zwane<sup>13</sup>,  
12 Kathy Mngadi<sup>13</sup>, William Brumskine<sup>13</sup>, Nivashnee Naicker<sup>1</sup>, Disebo Potloane<sup>1</sup>, Sharlaa Badal-  
13 Faesen<sup>14</sup>, Steve Innes<sup>15</sup>, Shaun Barnabas<sup>16</sup>, Johan Lombaard<sup>17</sup>, Katherine Gill<sup>15</sup>,  
14 Maphoshane Nchabeleng<sup>18</sup>, Elizma Snyman<sup>19</sup>, Friedrich Petrick<sup>20</sup>, Elizabeth Spooner<sup>21</sup>,  
15 Logashvari Naidoo<sup>21</sup>, Dishiki Kalonji<sup>21</sup>, Vimla Naicker<sup>21</sup>, Nishanta Singh<sup>21</sup>, Rebene Mabo<sup>22</sup>,  
16 Pamela Mda<sup>23</sup>, Daniel Malan<sup>24</sup>, Anusha Nana<sup>25</sup>, Mookho Malahleha<sup>26</sup>, Philip Kotze<sup>27</sup>, Jon J.  
17 Allagappen<sup>28</sup>, Andreas H. Diacon<sup>29</sup>, Gertruida M. Kruger<sup>30</sup>, Faezah Patel<sup>31</sup>, Penny L.  
18 Moore<sup>1,9,10</sup>, Wendy A. Burgers<sup>11,12</sup>, Kate Anteyi<sup>32</sup>, Brett Leav<sup>32</sup>, Linda-Gail Bekker<sup>15</sup>, Glenda E  
19 Gray<sup>33</sup>, Ameena Goga<sup>34,35</sup> and the SHERPA study team

21 **Affiliations:**

- 22 1. Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
- 23 2. Discipline of Public Health Medicine, School of Nursing and Public Health, University of  
24 KwaZulu-Natal, Durban, South Africa
- 25 3. Biostatistics Research Unit, South African Medical Research Council (SAMRC), Durban,  
26 South Africa
- 27 4. Hutchinson Center Research Institute of South Africa, Cape Town, South Africa
- 28 5. Grants, Innovation and Product Development Unit, SAMRC, Durban, South Africa

- 29 6. Right to Care, Johannesburg, Gauteng, South Africa
- 30 7. Division of Public Health Surveillance and Response, National Institute for  
31 Communicable Diseases (NICD) of the National Health Laboratory Services (NHLS),  
32 Johannesburg, South Africa
- 33 8. Burden of Disease Research Unit, SAMRC, Tygerberg, South Africa
- 34 9. SAMRC Antibody Immunity Research Unit, School of Pathology, University of the  
35 Witwatersrand, Johannesburg, South Africa.
- 36 10. Centre for HIV and STIs, NICD of the NHLS, Johannesburg, South Africa.
- 37 11. Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology,  
38 Department of Pathology, University of Cape Town, Cape Town, South Africa
- 39 12. Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town,  
40 Cape Town, South Africa
- 41 13. Aurum Institute, Johannesburg, South Africa
- 42 14. Clinical HIV Research Unit, Johannesburg, South Africa
- 43 15. Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
- 44 16. Family Centre for Research with Ubuntu, Tygerberg, South Africa
- 45 17. Josha Research, Bloemfontein, South Africa
- 46 18. Medunsa Clinical Research Unit, Sefako Makgatho Health Sciences University, Pretoria,  
47 South Africa
- 48 19. TASK Eden, George, South Africa
- 49 20. Mzansi Ethical Research Centre, Middelburg, South Africa
- 50 21. SAMRC Clinical Research Site, Durban South Africa
- 51 22. Ndlovu Research Centre, Elandsdoorn, South Africa
- 52 23. Nelson Mandela Academic Research Unit CRS, Mthatha, South Africa
- 53 24. PHOENIX Pharma, Port Elizabeth, South Africa
- 54 25. Perinatal HIV Research Unit, Johannesburg, South Africa
- 55 26. Synergy Biomed Research Institute, East London, South Africa
- 56 27. Qhakaza Mbokodo Research Clinic, Ladysmith, South Africa

- 57 28. Setshaba Research Centre, Soshanguve, South Africa
- 58 29. TASK Central, Cape Town, South Africa
- 59 30. Ubuntu Clinical Research, Gauteng, South Africa
- 60 31. Wits RHI Research Institute, University of Witwatersrand, Johannesburg, South Africa
- 61 32. Moderna Inc., Cambridge, MA, USA
- 62 33. Office of the President and CEO, SAMRC, Cape Town, South Africa
- 63 34. Department of Paediatrics and Child Health, University of Pretoria, Pretoria, South Africa
- 64 35. HIV and other Infectious Diseases Research Unit, SAMRC, Durban, South Africa

65

66 **Corresponding Author:** Prof Nigel Garrett; 2<sup>nd</sup> Floor, Doris Duke Medical Research  
67 Institute (Private Bag X7), 719 Umbilo Road, Congela, Durban 4013, South Africa;  
68 Email: [nigel.garrett@caprisa.org](mailto:nigel.garrett@caprisa.org); Phone: +27 31 655 0617

69

70 **Keywords:** SARS-CoV-2, COVID-19, Ad26.COV2.S, mRNA-1273, vaccine, booster

71

72 **Word counts:**

73 Abstract: 300/300

74 Text: 3866

75 Tables/Figures: 3 Tables and 3 Figures

76

77

## 78 Abstract

79 Given limited data on safety and effectiveness of heterologous COVID-19 vaccine boosting  
80 in lower income, high-HIV prevalence settings, we evaluated a mRNA-1273 boost after  
81 Ad26.CO2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3  
82 study nested in the Sisonke implementation trial of 500000 healthcare workers (HCWs).  
83 Sisonke participants were offered mRNA-1273 boosters between May and November 2022,  
84 a period of circulating Omicron sub-lineages. Adverse events (AE) were self-reported, and  
85 co-primary endpoints (SARS-CoV-2 infections and COVID-19 hospitalizations or deaths)  
86 were collected through national databases. We used Cox regression models with booster  
87 status as time-varying covariate to determine the relative vaccine effectiveness (rVE) of the  
88 mRNA-1273 booster among SHERPA versus unboosted Sisonke participants. Of 11248  
89 SHERPA participants in the rVE analysis cohort (79.3% female, median age 41), 45.4% had  
90 received one and 54.6% two Ad26.CO2.S doses. Self-reported comorbidities included HIV  
91 (18.7%), hypertension (12.9%) and diabetes (4.6%). In multivariable analysis including  
92 413161 unboosted Sisonke participants, rVE of the booster was 59% (95%CI 29-76%)  
93 against SARS-CoV-2 infection: 77% (95%CI 9–94%) in the one-Ad26.CO2.S dose group  
94 and 52% (95%CI 13-73%) in the two-dose group. Severe COVID-19 was identified in 148  
95 unboosted participants, and only one SHERPA participant with severe HIV-related  
96 immunosuppression. Of 11798 participants in the safety analysis, 271 (2.3%) reported a  
97 reactogenicity event or unsolicited AE, more among those with prior SARS-CoV-2 infections  
98 (adjusted odds ratio [aOR] 2.03, 95%CI 1.59-2.59) and less among people living with HIV  
99 (PLWH) (aOR 0.49, 95%CI 0.34-0.69). No related serious AEs were reported. In an  
100 immunogenicity sub-study, mRNA-1273 increased antibody functions and T-cell responses 4  
101 weeks after boosting regardless of the number of prior Ad26.CO2.S doses, or HIV status,  
102 and generated Omicron spike-specific cross-reactive responses. mRNA-1273 boosters after  
103 one or two Ad26.CO2.S doses were well-tolerated, safe and effective against Omicron  
104 SARS-CoV-2 infections among HCWs and PLWH.

105

**Trial Registration:** The SHERPA study is registered in the Pan African Clinical Trials Registry (PACTR): PACTR202310615330649 and the South African National Clinical Trial Registry (SANCTR): DOH-27-052022-5778.

## INTRODUCTION

During the first 2 years of the COVID-19 pandemic, populations in low- and middle-income countries (LMICs) had limited access to mRNA vaccines. Instead, most LMICs including South Africa, started their vaccination programmes with vector-based vaccines, such as Ad26.COVS2.S (Janssen/Johnson & Johnson) and ChAdOx1-S (Oxford/AstraZeneca). When vaccine demand subsided in high-income countries and production increased, mRNA vaccines by Pfizer-BioNTech and Moderna became available, allowing for a heterologous boosting strategy in LMICs. While this strategy was supported by immunogenicity data and by programmatic evaluations<sup>1,2</sup>, it was not formally investigated in clinical trials, meaning there was limited evidence on safety and effectiveness of mRNA booster vaccinations after the Ad26.COVS2.S vaccine, especially from LMICs with high HIV prevalence.

In South Africa, the COVID-19 vaccination rollout started in February 2021, when half a million healthcare workers received a single dose of Ad26.COVS2.S in the Sisonke phase 3b implementation trial<sup>3</sup>, just before the rapid spread of the SARS-CoV-2 Delta variant. Through monitoring of national COVID-19 databases, Sisonke showed that a single dose of Ad26.COVS2.S was 67% (95% confidence interval [CI] 62–71%) effective against COVID-19-related hospitalisations and 83% (75–89%) against COVID-19-related deaths<sup>3</sup>. Following the release of the ENSEMBLE 2 trial results<sup>4,5</sup>, approximately half of the Sisonke participants opted for a second Ad26.COVS2.S dose between October and December 2021. By this time, South Africa experienced a surge in SARS-CoV-2 cases with the Omicron variant. Early data showed that the second Ad26.COVS2.S dose provided added protection against hospitalizations and deaths during the Omicron wave<sup>6</sup>.

Following the recommendation by the United States Food and Drug Administration to limit the use of the Ad26.COV2.S vaccine, because of rare reported events of thrombosis with thrombocytopenia syndrome, and emerging data showing superior neutralizing antibody responses after mRNA vaccines, there was an urgent need to clarify the safety, immunogenicity and effectiveness of a heterologous vaccination approach in LMICs. Considering this, the Sisonke study team rapidly implemented and conducted the SHERPA study nested in Sisonke to investigate a heterologous mRNA-1273 boost after one or two doses of Ad26.COV2.S among healthcare workers in South Africa.

## METHODS AND MATERIALS

### *Study design and setting*

SHERPA (Sisonke Heterologous mRNA-1273 boost after Prime with Ad26.COV2.S) was a single-arm, open-label, phase 3 study, nested in the Sisonke trial, in which healthcare workers in South Africa had received one or two doses of Ad26.COV2.S between February and December 2021. In SHERPA, Sisonke participants were offered a mRNA-1273 booster dose (ancestral strain) at 30 clinical research sites (CRS) across South Africa, between 23 May 2022 and 12 November 2022. Using routinely collected national data, we aimed to compare SARS-CoV-2 infections and COVID-19-related hospitalizations and deaths among SHERPA participants with Sisonke participants who did not receive the mRNA-1273 booster (see study schema in **Supplementary Table 1**). The data cut-off for outcome ascertainment was 31 December 2022. Seven CRS followed 200 SHERPA participants for six months in a safety and immunogenicity sub-study. SHERPA was registered in the Pan African Clinical Trials Registry (PACTR202310615330649) and the South African National Clinical Trial Registry (DOH-27-052022-5778). All participants provided written informed consent.

### *Participants*

Sisonke participants were invited to join SHERPA via short messaging system (SMS) with a study website link, where they could register and choose a convenient CRS. SHERPA participants were 18 years or older with or without comorbidities, including HIV infection, were employed in the South African public or private healthcare sector, and had received either one or two doses of Ad26.COVS.2 in Sisonke. Considering the high COVID-19 morbidity among pregnant women, pregnant and breastfeeding women were eligible. Sisonke participants who had received any COVID-19 vaccine other than one or two doses of Ad26.COVS.2 (e.g., another mRNA booster) and those with evidence of SARS-CoV-2 infection within 14 days of enrolment were excluded (see **Supplementary Table 2** for full eligibility criteria).

### *Study procedures*

Once consented, the study team took a medical history, conducted a physical examination, and recorded any concomitant medications. Female participants of reproductive age had a pregnancy test, and all participants had a nasal swab taken for SARS-CoV-2 polymerase chain reaction (PCR) testing and a plasma sample to test for SARS-CoV-2 serology before vaccination. Participants in the safety and immunogenicity sub-study also had peripheral blood mononuclear cells (PBMC) and plasma samples taken before mRNA-1273 booster vaccination and 4 and 24 weeks after vaccination (see **Supplementary Tables 3 and 4**).

The 50mcg dose of the mRNA-1273 booster was prepared by research pharmacists. Clinical research staff then administered the vaccine in the deltoid muscle, and participants were monitored for 15 minutes for immediate reactogenicity events or allergic reactions. Adverse events (AE) experienced at the vaccination visit were managed and recorded by the CRS team. After the observation period, participants were issued with vaccination certificates, and CRS and Sisonke 'Safety Desk' contact details for AE reporting. Pregnant and breastfeeding women were followed up by the central safety team, through a pregnancy and breastfeeding registry that both the CRS and safety teams had access to.

189

## 190 *Immunogenicity sub-study*

191 Plasma and PBMC samples were taken before mRNA-1273 vaccination and 4 and 24 weeks  
192 after vaccination. We conducted SARS-CoV-2 spike enzyme linked immunosorbent assays  
193 (ELISA), SARS-CoV-2 nucleocapsid ELISA testing, a lentiviral pseudovirus neutralization  
194 assay, and an antibody-dependent cellular cytotoxicity (ADCC) assay at all timepoints.  
195 Neutralizing antibody responses in people living with HIV (PLWH) were tested using a  
196 vesicular stomatitis virus-based neutralization assay which was not subject to antiretroviral  
197 therapy interference<sup>7</sup>, and which produced equivalent titers to the lentiviral assay  
198 **(Supplementary Fig.1)**. T-cell responses to SARS-CoV-2 spike were measured from  
199 cryopreserved PBMC using intracellular cytokine staining and flow cytometry. This was  
200 performed on the first 50 participants with available PBMC samples at the three sampling  
201 visits (see Supplementary materials for immunogenicity assays).

202

## 203 *Data sources and data management*

204 We obtained SARS-CoV-2 and severity endpoint data through the surveillance system that  
205 was built for Sisonke **(Supplementary Fig.2)**. Data sources included the Notifiable Medical  
206 Conditions Sentinel Surveillance (NMCSS) database of SARS-CoV-2 cases, the DATCOV  
207 database of reported confirmed COVID-19 hospital admissions, and the national Electronic  
208 Vaccination Data System (EVDS) for COVID-19 vaccines. Automated near real-time  
209 deterministic and probabilistic linkage algorithms were applied to link these three routine  
210 COVID-19 datasets. Breakthrough SARS-CoV-2 infections, defined as a positive SARS-  
211 CoV-2 PCR or antigen test  $\geq 14$  days after booster vaccination, and COVID-19  
212 hospitalisations or deaths were identified through linking the databases.

213

214 SHERPA study visits were recorded in a Research Electronic Data Capture (REDCap)  
215 database (Vanderbilt University, Nashville, US). After the screening/enrolment visit, solicited  
216 and unsolicited AEs were self-reported via an online data entry link shared by SMS with

participants 1, 7 and 28 days after the booster. All safety events including Serious AEs (SAE) and AEs of Special Interest (AESI) were reviewed by safety clinicians and the Protocol Safety Review Team (PSRT). Data management systems were CFR Part 11 and POPIA compliant and processes followed Good Clinical Data Management Processes guidance.

### *Variables*

For the relative vaccine effectiveness (rVE) analysis, we used demographic and clinical variables that are routinely collected in the EVDS, including age, sex, common comorbidities, and geographic location. The NMCSS database provided information about previous SARS-CoV-2 infections.

### *Outcomes*

The co-primary outcomes were to assess the rVE of the mRNA-1273 booster by comparing the rates of SARS-CoV-2 infections and severe COVID-19 cases (defined as COVID-19 hospitalizations or deaths) among SHERPA participants compared to unboosted Sisonke participants. Secondary outcomes included an assessment of rVE of the mRNA-1273 booster against SARS-CoV-2 Infections, COVID-19 hospitalizations and deaths, in those who had received one or two doses of Ad26.COV2.S separately; an assessment of safety of the mRNA-1273 boost, including among pregnant women and PLWH; and comparisons of antibody and T-cell responses before and after vaccination.

### *Statistical analysis*

Analyses for the primary and secondary outcomes were performed using SAS version 9.4 (Statistical Analysis Software, North Carolina, USA) and Stata version 17 (College Station, TX, USA). Demographic and clinical data of participants enrolled in SHERPA and Sisonke were summarized using descriptive statistics including frequencies, proportions, and medians with interquartile ranges (IQR). For the primary analysis, we used a statistical

method proposed by Fintzi and Follmann<sup>8</sup> referred to here as an adjusted cohort approach, which allowed inclusion of SHERPA participants within the larger Sisonke cohort (Supplementary Fig.3).

We used a Cox regression model with the mRNA-1273 booster status as a time-varying covariate, adjusting for age, sex, an indicator of whether a participant had previously received one or two doses of Ad26.COV2.S, geographic location, number of comorbidities and evidence of prior SARS-CoV-2 infection. This time-varying exposure was characterized by a continuous piecewise linear function of time elapsed since the first mRNA-1273 dose (23 May 2022) for the log hazard ratio. Participants who did not experience an event of interest were censored on 31 December 2022 (cut-off date). The rVE in reducing the risk of SARS-CoV-2 infection and COVID-19 hospitalizations and deaths was estimated as one minus the estimated hazard ratio with 95% CI. Further details regarding outcome analyses, including an alternative matched cohort analysis approach, definitions of variables, and immunogenicity analyses are detailed in the **Statistical Analysis Plan**.

### *Study approvals*

The SHERPA and Sisonke trial protocols were approved by the South African Health Products Regulatory Authority (SAHPRA), and health research ethics committees of all participating CRSs. The study received full ethical approval by the following ethics committees in South Africa: Pharma-Ethics, Stellenbosch University Health Research Ethics Committee, University of KwaZulu-Natal Biomedical Research Ethics Committee, University of Cape Town Human Research Ethics Committee, Sefako Makgatho University Research Ethics Committee, The South African Medical Research Council Human Research Ethics Committee and the University of the Witwatersrand Human Research Ethics Committee.

## RESULTS

### *Study Population*

Of 501230 Sisonke participants who had received one or two Ad26.COV2.S doses between 17 February 2021 and 22 May 2022, 12342 enrolled into SHERPA and received the mRNA-1273 booster between 23 May 2022 and 12 November 2022 (**Fig.1**). Of these, 1094 (8.9%) were excluded from the rVE analysis, because they had either received a third Ad26.COV2.S or a BNT162b2 mRNA booster, or had received an Ad26.COV2.S vaccine after the earliest date of mRNA-1273 vaccination on 23 May 2022. Participants at one CRS had to be excluded from rVE and safety analyses due to concerns about data integrity. The mRNA-1273 booster rVE analysis included 11248 SHERPA participants, of whom 5102 (45.4%) had received one and 6146 (54.6%) two prior Ad26.COV2.S doses. These were compared to 413161 non-SHERPA Sisonke participants, of whom 185676 (44.9%) had received one and 227485 (55.1%) two doses of Ad26.COV2.S.

### **Figure 1: Flow Chart of the SHERPA Analysis Cohort nested in the Sisonke**

#### **Implementation Trial**

Baseline demographic and clinical characteristics of the SHERPA and non-SHERPA participants stratified by number of previous Ad26.COV2.S vaccinations are summarized in **Table 1**. The majority (79.3%) of SHERPA participants were female and median age was 41 years (IQR 35–48). One third (32.2%) of participants reported at least one comorbidity, most commonly HIV infection (18.7%), hypertension (12.9%) and diabetes (4.6%). Participants were recruited from all nine South African provinces. Non-SHERPA participants had similar characteristics, apart from fewer reporting HIV infection (8.3%).

300 **Table 1: Baseline Demographics and clinical Characteristics of SHERPA and non-**  
301 **SHERPA Participants previously vaccinated in Sisonke**

|                                                | SHERPA                           |                                    |                 | non-SHERPA             |                          |                   |
|------------------------------------------------|----------------------------------|------------------------------------|-----------------|------------------------|--------------------------|-------------------|
| Characteristic                                 | Ad26.COV2.S + mRNA-1273 (N=5102) | 2 Ad26.COV2.S + mRNA-1273 (N=6146) | Total (N=11248) | Ad26.COV2.S (N=185676) | 2 Ad26.COV2.S (N=227485) | Total (N= 413161) |
| <b>Sex, n (%)</b>                              |                                  |                                    |                 |                        |                          |                   |
| Female                                         | 4048 (79.3%)                     | 4877 (79.4%)                       | 8925 (79.3%)    | 136534 (73.5%)         | 171854 (75.5%)           | 308388 (74.6%)    |
| Male                                           | 1054 (20.7%)                     | 1269 (20.6%)                       | 2323 (20.7%)    | 49142 (26.5%)          | 55631 (24.5%)            | 104773 (25.4%)    |
| Median age (years), IQR                        | 40 (33-46)                       | 43 (36-50)                         | 41 (35-48)      | 40 (33-49)             | 44 (35-53)               | 42 (34-51)        |
| <b>Age groups (year), n (%)</b>                |                                  |                                    |                 |                        |                          |                   |
| 18-39                                          | 2538 (49.7%)                     | 2297 (37.4%)                       | 4835 (43.0%)    | 90048 (48.5%)          | 83720 (36.8%)            | 173768 (42.1%)    |
| 40-49                                          | 1743 (34.2%)                     | 2288 (37.2%)                       | 4031 (35.8%)    | 53390 (28.8%)          | 68471 (30.1%)            | 121861 (29.5%)    |
| 50-59                                          | 699 (13.7%)                      | 1257 (20.5%)                       | 1956 (17.4%)    | 31549 (17.0%)          | 53257 (23.4%)            | 84806 (20.5%)     |
| ≥60                                            | 122 (2.4%)                       | 304 (4.9%)                         | 426 (3.8%)      | 10628 (5.7%)           | 22034 (9.7%)             | 32662 (7.9%)      |
| Missing                                        | 0                                | 0                                  | 0               | 61 (<0.1%)             | 3 (<0.1%)                | 64 (<0.1%)        |
| <b>Number of comorbidities, n (%)</b>          |                                  |                                    |                 |                        |                          |                   |
| 0                                              | 3573 (70.0%)                     | 4048 (65.9%)                       | 7621 (67.8%)    | 141683 (76.3%)         | 166384 (73.1%)           | 308067 (74.6%)    |
| 1                                              | 1334 (26.1%)                     | 1792 (29.2%)                       | 3126 (27.8%)    | 37390 (20.1%)          | 50328 (22.1%)            | 87718 (21.2%)     |
| ≥2                                             | 195 (3.8%)                       | 304 (4.9%)                         | 501 (4.5%)      | 6603 (3.6%)            | 10773 (4.7%)             | 17376 (4.2%)      |
| <b>Risk factors for severe COVID-19, n (%)</b> |                                  |                                    |                 |                        |                          |                   |
| Living with HIV                                | 977 (19.1%)                      | 1122 (18.3%)                       | 2099 (18.7%)    | 17612 (9.5%)           | 16572 (7.3%)             | 34184 (8.3%)      |
| Hypertension                                   | 541 (10.6%)                      | 912 (14.8%)                        | 1453 (12.9%)    | 23007 (12.4%)          | 38094 (16.7%)            | 61101 (14.8%)     |
| Diabetes                                       | 188 (3.7%)                       | 332 (5.4%)                         | 520 (4.6%)      | 8382 (4.5%)            | 14471 (6.4%)             | 22853 (5.5%)      |
| Cancer                                         | 5 (0.1%)                         | 15 (0.2%)                          | 20 (0.2%)       | 355 (0.2%)             | 680 (0.3%)               | 1035 (0.3%)       |
| Tuberculosis                                   | 10 (0.2%)                        | 12 (0.2%)                          | 22 (0.2%)       | 236 (0.1%)             | 209 (0.1%)               | 445 (0.1%)        |
| Heart disease                                  | 9 (0.2%)                         | 26 (0.4%)                          | 35 (0.3%)       | 974 (0.5%)             | 1661 (0.7%)              | 2635 (0.6%)       |
| Chronic lung disease                           | 5 (0.1%)                         | 14 (0.2%)                          | 19 (0.2%)       | 481 (0.3%)             | 901 (0.4%)               | 1382 (0.3%)       |
| <b>Geographical location, n (%)</b>            |                                  |                                    |                 |                        |                          |                   |
| Eastern Cape                                   | 762 (14.9%)                      | 838 (13.6%)                        | 1600 (14.2%)    | 25454 (13.7%)          | 24773 (10.9%)            | 50227 (12.2%)     |
| Free State                                     | 209 (4.1%)                       | 308 (5.0%)                         | 517 (4.6%)      | 8123 (4.4%)            | 11926 (5.2%)             | 20049 (4.9%)      |
| Gauteng                                        | 1884 (36.9%)                     | 1918 (31.2%)                       | 3802 (33.8%)    | 51952 (28.0%)          | 61629 (27.1%)            | 113581 (27.5%)    |
| KwaZulu-Natal                                  | 1255 (24.6%)                     | 1464 (23.8%)                       | 2719 (24.2%)    | 41449 (22.3%)          | 39044 (17.2%)            | 80493 (19.5%)     |

|               |             |              |              |               |               |               |
|---------------|-------------|--------------|--------------|---------------|---------------|---------------|
| Limpopo       | 63 (1.2%)   | 93 (1.5%)    | 156 (1.4%)   | 11188 (6.0%)  | 17517 (7.7%)  | 28705 (6.9%)  |
| Mpumalanga    | 227 (4.4%)  | 187 (3.0%)   | 414 (3.7%)   | 10140 (5.5%)  | 9107 (4.0%)   | 19247 (4.7%)  |
| North West    | 184 (3.6%)  | 213 (3.5%)   | 397 (3.5%)   | 9073 (4.9%)   | 10875 (4.8%)  | 19948 (4.8%)  |
| Northern Cape | 4 (0.1%)    | 1 (0.0%)     | 5 (0.0%)     | 3251 (1.8%)   | 4701 (2.1%)   | 7952 (1.9%)   |
| Western Cape  | 514 (10.1%) | 1124 (18.3%) | 1638 (14.6%) | 25046 (13.5%) | 47913 (21.1%) | 72959 (17.7%) |

#### *Prior SARS-CoV-2 infections and time since last vaccination*

Participants were checked against the NMCSS database for evidence of previous SARS-CoV-2 infection. Among SHERPA participants 1079 (9.2%) had evidence of a previous SARS-CoV-2 infection compared to 54770 (13.3%) among the non-SHERPA group. Overall, these estimates were likely an underestimate considering higher self-report rates (28%) and evidence of high prevalence of baseline seropositivity in the immunogenicity sub-study. The median days between the last Ad26.COVID.S dose and 23 May 2022 (SHERPA start) was 188 days (IQR 171-419) among SHERPA participants and 189 days (IQR 172-406) among the non-SHERPA group (**Table 2**).

**Table 2: Recorded prior COVID-19 Infections among SHERPA and non-SHERPA**

**Participants nested in the Sisonke Study**

|                                                                                                                                                                              | SHERPA                                 |                                          |                    | non-SHERPA                |                             |                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|------------------------------------------|--------------------|---------------------------|-----------------------------|----------------------|
| Characteristic                                                                                                                                                               | Ad26.COV2.S<br>+ mRNA-1273<br>(N=5102) | 2 Ad26.COV2.S<br>+ mRNA-1273<br>(N=6146) | Total<br>(N=11248) | Ad26.COV2.S<br>(N=185676) | 2 Ad26.COV2.S<br>(N=227485) | Total<br>(N= 413161) |
| Documented<br>previous SARS-<br>CoV-2 infection*                                                                                                                             | 398 (7.8%)                             | 629 (10.2%)                              | 1027<br>(9.2%)     | 21480 (11.6%)             | 33290 (14.6%)               | 54770<br>(13.3%)     |
| Recent prior<br>infection <sup>#</sup>                                                                                                                                       | 20 (0.4%)                              | 77 (1.2%)                                | 97 (0.9%)          | 2422 (1.3%)               | 6945 (3.1%)                 | 9367 (2.3%)          |
| Non-recent prior<br>infection <sup>+</sup>                                                                                                                                   | 378 (7.4%)                             | 552 (9.0%)                               | 930 (8.3%)         | 19058 (10.3%)             | 26345 (11.6%)               | 45403<br>(11.0%).    |
| <b>Days between last Ad26.COV2.S dose and (i) earliest date of a participant receiving the mRNA-1273 (SHERPA group) or (ii) enrolment as a comparator (non-SHERPA group)</b> |                                        |                                          |                    |                           |                             |                      |
| Median, IQR                                                                                                                                                                  | 424 (382 - 443)                        | 172 (153 - 181)                          | 188 (171 - 419)    | 418 (378 - 437)           | 173 (159 - 182)             | 189 (172 - 406)      |

\*Infection on or before 23 May 2022; Both PCR and antigen tests considered.

<sup>#</sup>Recent infection means less ≤ 90 days before enrollment for SHERPA participants and < 90 days before SHERPA study start 23 May 2022 for non-SHERPA participants.

<sup>+</sup>Non- recent infection means less > 90 days before enrollment for SHERPA participants and > 90 days before non-SHERPA participants study start 23 May 2022 for non-SHERPA participants.

### *SARS-CoV-2 infection and severe COVID-19 endpoints*

As of 31 December 2022, after 3056 person-years of follow up, there were 13 recorded SARS-CoV-2 infections among SHERPA participants at median 125 days (IQR 90-154) after mRNA-1273 boosting. In contrast, 3352 infections were recorded among the non-SHERPA group after 251104 years of follow-up (**Supplementary Table 5**). There were 148 COVID-19 hospitalization or deaths among the non-SHERPA group compared to one among SHERPA participants. This immunocompromised PLWH, with a CD4 count of less than 200 cells/mm<sup>3</sup>

and high HIV viremia, died of COVID-19 pneumonia with respiratory distress syndrome, six months after receiving the mRNA-1273 booster.

#### *Relative vaccine effectiveness of the mRNA-1273 booster*

Comparing SHERPA participants to the non-SHERPA group, the unadjusted analysis showed a rVE of 59% (95%CI 29-76%) against SARS-CoV-2 infection, which did not change after adjusting for age, sex, prior SARS-CoV-2 infection, prior vaccination and geographic location (**Table 3**). The adjusted rVE of the booster among participants who had one prior Ad26.COVID.S dose was 77% (95%CI 9-94%) and 52% (95%CI 13-73%) for those who had two prior Ad26.COVID.S doses. In a separate model adjusting for HIV the rVE estimate only slightly changed to 57% (95%CI 25-75%). With only one severe COVID-19 case among SHERPA participants and few severe endpoints overall, the rVE estimate for COVID-19 hospitalizations and deaths lacked precision (**Supplementary Table 6**). In the alternative matched cohort analysis, the overall rVE against SARS-CoV-2 infection was slightly higher at 63% (95%CI 32-82%) (**Supplementary Tables 7 and 8**).

**Table 3: Relative Vaccine Effectiveness of mRNA-1273 Booster against SARS-CoV-2 Infection**

|                                                            | Unadjusted     | Adjusted*: Model with comorbidities |
|------------------------------------------------------------|----------------|-------------------------------------|
|                                                            | VE (95% CI)    | VE (95% CI)                         |
| <b>Primary Endpoint</b>                                    |                |                                     |
| <b>SARS-CoV-2 Infection</b>                                | 59% (29 - 76%) | 59% (29 - 76%)                      |
| <b>Secondary Endpoints</b>                                 |                |                                     |
| <b>SARS-CoV-2 infections after 1 previous Ad26.COVID.S</b> | 77% (8 - 94%)  | 77% (9 - 94%)                       |
| <b>SARS-CoV-2 infections after 2 previous Ad26.COVID.S</b> | 51% (13 - 73%) | 52% (13 - 73%)                      |

\*Adjusted for age, sex, prior COVID, prior vaccination, geographical location

361

# 362 *Safety profile of mRNA-1273 booster*

363 Of 11798 SHERPA participants included in the safety analysis, 228 (1.9%) participants  
364 reported 575 reactogenicity events within 7 days after the mRNA-1273 booster. Of these,  
365 230/575 (40%) were local reactogenicity events including 97/230 (42.2%) injection site pain,  
366 69/230 (30%) swelling, 32/230 (13.9%) induration and 32/230 (13.9%) erythema events. A  
367 total of 345 systemic reactogenicity events were reported including 123 (35.7%) malaise  
368 and/or myalgia, 120 (34.8%) headache, 66 (19.1%) fever, 17 (4.9%) chills, 10 (2.9%)  
369 nausea, 5 (1.4%) vomiting and 4 (1.2%) arthralgia. All reported local and systemic  
370 reactogenicity were mild or moderate (grade 1 or 2) and all resolved without sequelae.

371

372 Unsolicited AEs collected for 28 days after vaccination and those meeting SAE/AESI criteria  
373 collected until the end of study participation were reported by 98 (0.8%) participants,  
374 reporting a total of 115 events. Of these events, 17 events met SAE criteria. Three of the 17  
375 SAEs also met AESI criteria, the other 4 AESIs were grade 1 and 2 anosmia and ageusia,  
376 which resolved without sequelae. No related SAEs were reported during the study.

377

378 More reactogenicity events were reported by participants with prior SARS-CoV-2 infection  
379 (3.6% vs 1.8%), HIV-negative status (2.7% vs 1.2%) and those who received two compared  
380 to one prior Ad26.COV2.S dose (2.6% vs 2.0%). In a logistic regression model adjusting for  
381 age and sex, a prior SARS-CoV-2 infection (adjusted odds ratio [aOR] =2.03, 95%CI 1.59-  
382 2.59) and an HIV positive status (aOR=0.49, 95%CI 0.34-0.69) were associated with  
383 local/systemic reactions, but not having received two versus one Ad26.COV2.S dose before  
384 the mRNA-1273 booster (aOR=1.26, 95%CI 0.99-1.62), **Supplementary Table 9**.

385

386 Among 70 confirmed pregnancies, there were 39 (55.7%) full-term births, 4 (5.7%) preterm  
387 births (<37 weeks gestation), 11 (15.7%) early miscarriages (<12 weeks gestation), 7  
388 (10.0%) stillbirths (>20 weeks gestation), and one (1.4%) ectopic pregnancy. Six (8.6%)

women opted for an elective termination of pregnancy and two (2.9%) were lost to follow-up. All adverse outcomes, including miscarriages, preterm births and stillbirths were evaluated and deemed unrelated to vaccination by CRS investigators and the PSRT. Preterm births were reported in women with hypertension in pregnancy and multiple gestations, while the stillbirths (experienced by women aged 32 to 44 years) were evaluated as associated with abruptio placenta, postdate, cord around the fetal neck, and complicated home delivery (**Supplementary Table 10**).

### *Immune responses after mRNA-1273 booster*

Baseline neutralizing antibody titers were 2-3 fold higher in participants who had received 2 doses versus 1 dose of Ad26.COV2.S (median: 1311 vs 3269 for D614G and 508 vs 1281 for BA.4) (**Fig. 2A,B**). The mRNA-1273 boost resulted in increased neutralizing antibodies titers for D614G after 4 weeks and then a decline by 24 weeks among those with one and two doses of Ad26.COV2.S (median baseline, 4-week and 24-week titers of 1311, 7033 and 2220 for the 1-dose group and 3269, 17653, 5526 for the 2-dose group), **Fig. 2A-C**. The antibody response after boosting was less pronounced towards the BA.4 pseudovirus despite a significant increase in rVE against this variant of concern. Baseline spike-binding antibody titers were comparable regardless of the number of previous Ad26.COV2.S doses. Binding titers significantly increased up to 6-fold 4 weeks post-boost (**Fig. 2D,E**), while ADCC had smaller but significant increases post-boost (**Fig. 2F,G**). The binding and ADCC titers were lower 6 months after the boost, with similar titers observed between both Ad26.COV2.S groups (**Fig. 2D-G**). At baseline, PLWH had up to 3-fold lower binding antibody titers and up to 2-fold lower neutralizing activity against D614G compared to HIV negative participants, irrespective of prior Ad26.COV2.S doses, while ADCC levels were similar (**Supplementary Fig.4**). Antibody functions in PLWH followed similar trends after the booster as HIV-negative participants.

## Figure 2: Antibody Response elicited after mRNA-1273 heterologous Boost

**Legend:** Plasma from a subset of participants were assessed to determine the antibody response elicited upon heterologous boost (mJnJ) after 1 Ad26.COVS.S dose (JnJ x1; n=19) or 2 Ad26.COVS.S doses (JnJ x2; n=29). The neutralization activity was measured using a SARS-CoV-2 pseudovirus-based neutralization assay with (panel A) D614G, (panel B) Omicron BA.4 and (panel C) D614G in people living with HIV (PLWH). The plasma neutralization titer is measured as an ID<sub>50</sub>. Black horizontal bars represent medians. The threshold of detection for the neutralization assay is an ID<sub>50</sub> of 20. Antibody binding was measured using an in-house SARS-CoV-2 assay using the D614G full spike protein (panel D and E). An EC50 was used to measure the binding titers of the samples. ADCC activity was measured by detecting the crosslinking ability of the antibodies present in the serum (panel F and G). Relative light units were measured which correlate with the levels of FcγRIIIa signalling. For all assays, statistical significance was measured with the Kruskal-Wallis test with Dunn's multiple comparisons test. Significance is shown as: \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 and \*\*\*\*p < 0.0001. Medians and fold changes are depicted under each graph. Samples were run in duplicate for all assays. Nucleocapsid ELISA was used to identify prior SARS-CoV-2 infections. Only individuals who were seropositive at baseline were included in the analysis as there was only 1 nucleocapsid-seronegative participants in the JnJ x1 group.

We examined T-cell responses in a subset of 50 participants (**Fig. 3A**). At baseline, spike-specific CD4+ T-cell responses were detected in 96% of participants (**Fig. 3B**). Four weeks after mRNA-1273 boosting, the frequency increased 2-fold (median: 0.074% vs 0.169%, p<0.0001), followed by contraction to a median of 0.113% by 24 weeks, which was not significantly different from baseline. Spike-specific CD8+ T-cell responses occurred in 52% of participants at baseline, and followed a similar trajectory as CD4 responses, increasing significantly at 4 weeks (median: 0.034% vs 0.057%, p=0.0029; **Fig. 3C**) and waning to 0.047% by 24 weeks. When examining the effect of prior vaccination with Ad26.COVS.S (**Fig. 3D**), there were significantly higher CD4+ responses at baseline in those who received

two compared to one prior dose, which persisted at all timepoints after mRNA-1273 boosting. In contrast, the magnitude of CD8+ responses was similar between those who received one or two Ad26.COV2.S doses. HIV infection had no negative impact on vaccine booster responses at 4 or 24 weeks (**Fig. 3E**). When examining T-cell cross-reactivity to Omicron sub-lineages, we observed a high degree of preservation of the T-cell responses to Omicron BA.1, BA.4/5 and XBB.1 (**Fig. 3F-G**).

### **Figure 3: T-cell Response elicited after mRNA-1273 heterologous Boost**

**Legend:** (A) Clinical characteristics of the T-cell sub-study cohort. Frequency of spike-specific CD4+ (B) and CD8+ (C) T-cells producing any of the measured cytokines (IFN- $\gamma$  IL-2 or TNF- $\alpha$ ) in response to stimulation with a peptide pool spanning ancestral spike protein at baseline (BL), week 4 (W4) and week 24 (W24), in participants vaccinated with one or two prior doses of Ad26.COV2.S and an mRNA-1273 booster. The median response and proportion of participants with a spike-specific CD4+ or CD8+ T-cell responses are indicated below the graphs. (D) Spike-specific CD4+ and CD8+ T-cell cytokine responses stratified according to number of Ad26.COV2.S doses received. (E) Spike CD4+ and CD8+ T-cells in HIV-uninfected participants (pink) or PLWH (red). (F) Spike-specific CD4+ T-cell responses to spike from ancestral virus and Omicron sub-lineages BA.1, BA.4/5 and XBB.1. (G) Fold change of Omicron sub-lineage responses compared to ancestral spike. Bars represent the medians. Differences between responses at different time points post boost were assessed using a two-tailed Wilcoxon paired test. Differences between participants vaccinated with one or two doses of Ad26.COV2.S and responses to different SARS-CoV-2 variants were calculated using a Mann-Whitney U test. The number of participants included in each analysis is indicated on the graphs.

## DISCUSSION

Nested in the Sisonke phase 3b implementation study, the SHERPA trial showed that one mRNA-1273 booster administered after 1 or 2 doses of Ad26.COVS.2 was safe and well tolerated regardless of HIV status, comorbidities or prior SARS-CoV-2 infection. The mRNA-1273 booster had a rVE of 59% (29-76%) in preventing SARS-CoV-2 infections overall, 77% (9-94%) after one Ad26.COVS.2 dose and 52% (13-73%) after 2 Ad26.COVS.2 doses up to 7 months after the boost. Breakthrough infections occurred during the Omicron wave (**Supplementary Fig. 5**), thus the data confirm the benefit of heterologous mRNA-1273 boosting after priming with Ad26.COVS.2 against Omicron sub-lineages.

The additional benefit of the mRNA-1273 booster was particularly high among participants who had only received a single Ad26.COVS.2 previously, also indicating that the booster was especially effective among those who had received their vaccine dose more than a year previously. This finding also corroborated with strong antibody and T-cell immune responses elicited by the booster in the immunogenicity sub-study. Consistent with epidemiological data on the evolving COVID-19 pandemic, few severe COVID-19 cases were detected in the Sisonke cohort and only a single case among SHERPA participants, thereby not providing sufficient statistical power for a meaningful interpretation of rVE against COVID-19 hospitalizations and deaths.

Our findings for heterologous boosting corroborate with studies reporting on homologous mRNA-1273 boosting in the USA. In one study the rVE of a homologous mRNA-1273 boost against SARS-CoV-2 infection was 61% (95%CI 60–62%) among immunocompetent adults receiving the booster  $\geq 150$  days after priming during the Omicron wave<sup>9</sup>. In a second study amongst US veterans receiving a third homologous mRNA-1273 booster during the Omicron wave, the rVE was 64% (95%CI 63-65%) compared with a rVE of 12% (95%CI 10-15%) for 2-dose vaccination<sup>10</sup>.

Earlier in the pandemic, studies assessed the VE of a heterologous prime-boost approach. One study from Sweden with 16402 participants receiving ChAdOx1 nCoV-19 prime followed by a mRNA-1273 boost found a VE of 79% (95%CI, 62-88%) against symptomatic COVID-19 infection compared with unvaccinated controls during the Delta wave<sup>11</sup>. An almost identical rVE was found in a study conducted across emergency departments in the USA for people who received a single Ad26.COV2.S dose followed by a mRNA-1273 boost<sup>12</sup>.

Our findings indicate that in LMICs where vaccine availability has been limited and HIV prevalence, co-morbidities and prior SARS-CoV-2 infection are high, a heterologous mRNA-1273 boost, using ancestral vaccine after one or two Ad26.COV2.S vaccinations was protective against SARS-CoV-2 infection in healthcare workers during the Omicron wave. Our data also confirms the safety of an mRNA-1273 boost after Ad26.COV2.S priming amongst healthcare workers, including PLWH, people with comorbidities and pregnant women.

Previous epidemiological studies on pregnancy outcomes and placental studies have shown that mRNA vaccines are safe in pregnancy and that there is negligible uptake and inflammatory responses within placental tissues post vaccination<sup>13,14,15</sup>. In South Africa, only 68.3% of pregnant women have their first antenatal visit before 20 weeks gestation<sup>16</sup>, meaning that national data on early pregnancy losses are limited. However, early pregnancy losses observed in SHERPA (15.7%) were comparable to other clinical trial cohorts (6.1-17.9%), which included early pregnancy testing and pregnancy outcome tracking<sup>17,18</sup>. Stillbirths reported in this study (10.0%) were associated with polymorbid conditions, including abruptio placenta, cord round the fetal neck and postdate, that provided clear alternative causes to the occurrence of the events. While the stillbirth rate was higher than in two clinical trial cohorts among younger, HIV negative women in HIV vaccine trials (1.5-3.5%), our data are in keeping with a 10% increase in stillbirths noted nationally in recent

review periods<sup>19</sup>, as well as the generally higher stillbirth rates reported among older cohorts and cohorts of PLWH<sup>20,21,22</sup>.

Antibody responses were higher among participants with two compared to one prior Ad26.COV2.S dose and were boosted with a heterologous mRNA vaccine among both groups, as reported previously<sup>2,23,24</sup>. Despite some evidence that Ad26.COV2.S may lead to slower waning of immune responses than mRNA vaccines<sup>25,26</sup>, the decline of antibody responses at 6 months in SHERPA suggests that the Ad26.COV2.S as a primary dose(s) may not significantly increase the durability of mRNA-boosted antibody responses. Although PLWH had lower antibody responses at baseline, mRNA-1273 boosting resulted in comparable titers to HIV-negative participants. mRNA-1273 boosting increased spike-specific T-cell responses, as described previously for heterologous vaccination regimens<sup>2,27</sup>. These responses were durable and highly cross-reactive to Omicron sub-lineages.

SHERPA had some limitations. First, it was a single arm trial nested in the larger Sisonke trial. As in Sisonke, we relied on routinely collected data to ascertain COVID-19 endpoints. However, this applied to both mRNA-1273 boosted and unboosted study groups, therefore reducing the potential for reporting bias. Second, we observed too few severe COVID-19 endpoints to allow for a well-powered assessment of rVE against severe disease. Contributing factors could have been that SHERPA was conducted during the Omicron wave, when generally less severe disease was reported<sup>28</sup>, South Africa has a high SARS-CoV-2 seroprevalence of up to 80%<sup>29</sup>, and all participants had at least received one dose of Ad26.COV2.S previously. Finally, we were unable to compare pregnancy outcomes in the SHERPA study with the larger Sisonke trial population, because pregnant women were initially not eligible for Sisonke, and pregnancy outcomes were not systematically collected.

Our data show that a heterologous mRNA-1273 boost following one or two Ad26.COV2.S priming among healthcare workers including those with HIV, comorbidities and pregnancy

can be included in national policy. We also demonstrate that boosting with the ancestral mRNA-1273 vaccine is still effective despite the evolution of SARS-CoV-2 into Omicron sub-lineage. This is important as variant vaccines may not be accessible in these settings. In conclusion, the SHERPA trial showed a high rVE of the mRNA-1273 booster during the Omicron wave among healthcare workers who had received one or two previous doses of Ad26.COV2.S. The heterologous booster was safe and well tolerated, immunogenic and effective in a LMIC with high HIV prevalence.

### **Declaration of Interests**

KA and BL are employees of Moderna, Inc. and may hold stock/stock options in the company. The other authors declare no conflict of interests.

### **Authorship contributions**

**Conceptualization:** Nigel Garrett, Linda-Gail Bekker, Glenda E Gray, Ameena Goga

**Data curation:** Nigel Garrett, Azwidhwi Takalani, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou, Thandeka Moyo-Gwete, Craig Innes, Zwelethu Zwane, Kathy Mngadi, William Brumskine, Nivashnee Naicker, Disebo Potloane, Sharlaa Badal-Faesen, Steve Innes, Shaun Barnabas, Johan Lombaard, Katherine Gill, Maphoshane Nchabeleng, Elizma Snyman, Friedrich Petrick, Elizabeth Spooner, Logashvari Naidoo, Dishiki Kalonji, Vimla Naicker, Nishanta Singh, Rebone Maboja, Pamela Mda, Daniel Malan, Anusha Nana, Mookho Malahleha, Philip Kotze, Jon J. Allagappen, Andreas H. Diacon, Gertruida M. Kruger, Faezah Patel, Penny L. Moore, Wendy A. Burgers, Linda-Gail Bekker, Glenda E Gray, Ameena Goga

**Formal analysis:** Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Ishen Seocharan, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou, Thandeka Moyo-Gwete, Penny L. Moore, Wendy A. Burgers

**Funding acquisition:** Nigel Garrett, Linda-Gail Bekker, Glenda E Gray, Ameena Goga

583 **Investigation:** Nigel Garrett, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Simone  
584 I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou,  
585 Thandeka Moyo-Gwete, Craig Innes, Zwelethu Zwane, Kathy Mngadi, William Brumskine,  
586 Nivashnee Naicker, Disebo Potloane, Sharlaa Badal-Faesen, Steve Innes, Shaun Barnabas,  
587 Johan Lombaard, Katherine Gill, Maphoshane Nchabeleng, Elizma Snyman, Friedrich  
588 Petrick, Elizabeth Spooner, Logashvari Naidoo, Dishiki Kalonji, Vimla Naicker, Nishanta  
589 Singh, Rebone Maboja, Pamela Mda, Daniel Malan, Anusha Nana, Mookho Malahleha,  
590 Philip Kotze, Jon J. Allagappen, Andreas H. Diacon, Gertruida M. Kruger, Faezaz Patel,  
591 Penny L. Moore, Wendy A. Burgers, Linda-Gail Bekker, Glenda E Gray, Ameena Goga  
592 **Methodology:** Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Waasila Jassat,  
593 Harry Moultrie, Ishen Seocharan, Jackline Odhiambo, Penny L. Moore, Wendy A. Burgers,  
594 Brett Leav, Linda-Gail Bekker, Glenda E Gray, Ameena Goga  
595 **Project administration:** Nigel Garrett, Azwidhwi Takalani, Kubashni Woeber, Ishen  
596 Seocharan, Jackline Odhiambo, Kentse Khuto, Kate Anteyi, Linda-Gail Bekker, Glenda E  
597 Gray, Ameena Goga  
598 **Resources:** Harry Moultrie, Penny L. Moore, Wendy A. Burgers, Kate Anteyi, Brett Leav,  
599 Glenda E Gray  
600 **Supervision:** Nigel Garrett, Azwidhwi Takalani, Penny L. Moore, Wendy A. Burgers, Linda-  
601 Gail Bekker, Glenda E Gray, Ameena Goga  
602 **Validation:** Tarylee Reddy, Nonhlanhla Yende-Zuma, Ishen Seocharan, Penny L. Moore,  
603 Wendy A. Burgers  
604 **Visualization:** Tarylee Reddy, Nonhlanhla Yende-Zuma, Ishen Seocharan, Simone I.  
605 Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou,  
606 Thandeka Moyo-Gwete  
607 **Writing – original draft:** Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Thandeka  
608 Moyo-Gwete, Penny L. Moore, Wendy A. Burgers, Ameena Goga  
609 **Writing – review & editing:** Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma,  
610 Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke

Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou, Thandeka Moyo-Gwete, Craig Innes, Zwelethu Zwane, Kathy Mngadi, William Brumskine, Nivashnee Naicker, Disebo Potloane, Sharlaa Badal-Faesen, Steve Innes, Shaun Barnabas, Johan Lombaard, Katherine Gill, Maphoshane Nchabeleng, Elizma Snyman, Friedrich Petrick, Elizabeth Spooner, Logashvari Naidoo, Dishiki Kalonji, Vimla Naicker, Nishanta Singh, Rebone Maboja, Pamela Mda, Daniel Malan, Anusha Nana, Mookho Malahleha, Philip Kotze, Jon J. Allagappen, Andreas H. Diacon, Gertruida M. Kruger, Faezah Patel, Penny L. Moore, Wendy A. Burgers, Kate Anteyi, Brett Leav, Linda-Gail Bekker, Glenda E Gray, Ameena Goga

## **Funding**

The SHERPA study was funded by Moderna, Inc. (Cambridge, Massachusetts, US) and the South African Medical Research Council (SAMRC). Moderna provided mRNA-1273 free-of-charge. The Sisonke trial was funded by: The National Department of Health through baseline funding to the SAMRC; the Solidarity Response Fund NPC; The Michael & Susan Dell Foundation; the ELMA Vaccines and Immunization Foundation (21-V0001); and the Bill & Melinda Gates Foundation (INV-030342). Moderna representatives reviewed the study protocol, participated in safety oversight, and contributed as manuscript co-authors, but were not involved in data collection and analysis.

## **Acknowledgements**

We thank the participants, the protocol and safety teams, the site-Principal Investigators, and their teams, the laboratory teams, SAHPRA, and the ethics committees for their contribution and oversight of the study.

## References

1. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *N Engl J Med* 2022; **386**(16): 1532-46.
2. Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19 Booster Vaccinations. *N Engl J Med* 2022; **386**(11): 1046-57.
3. Bekker LG, Garrett N, Goga A, et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. *Lancet* 2022; **399**(10330): 1141-53.
4. Hardt K, Vandebosch A, Sadoff J, et al. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Infect Dis* 2022; **22**(12): 1703-15.
5. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* 2021; **384**(23): 2187-201.
6. Gray G, Collie S, Goga A, et al. Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa. *N Engl J Med* 2022; **386**(23): 2243-5.
7. Bewley KR, Coombes NS, Gagnon L, et al. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. *Nat Protoc* 2021; **16**(6): 3114-40.
8. Fintzi J, Follmann D. Assessing vaccine durability in randomized trials following placebo crossover. *Stat Med* 2021; **40**(27): 5983-6007.
9. Florea A, Sy LS, Qian L, et al. Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults. *Clin Infect Dis* 2023; **76**(2): 252-62.

- 663 10. Young-Xu Y, Zwain GM, Izurieta HS, et al. Effectiveness of mRNA COVID-19 vaccines  
664 against Omicron and Delta variants in a matched test-negative case-control study  
665 among US veterans. *BMJ Open* 2022; **12**(8): e063935.
- 666 11. Nordstrom P, Ballin M, Nordstrom A. Effectiveness of heterologous ChAdOx1 nCoV-19  
667 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in  
668 Sweden: A nationwide cohort study. *Lancet Reg Health Eur* 2021; **11**: 100249.
- 669 12. Natarajan K, Prasad N, Dascomb K, et al. Effectiveness of Homologous and  
670 Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen  
671 [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency  
672 Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION  
673 Network, 10 States, December 2021-March 2022. *MMWR Morb Mortal Wkly Rep*  
674 2022; **71**(13): 495-502.
- 675 13. Pratama NR, Wafa IA, Budi DS, Putra M, Wardhana MP, Wungu CDK. mRNA Covid-  
676 19 vaccines in pregnancy: A systematic review. *PLoS One* 2022; **17**(2): e0261350.
- 677 14. Magnus MC, Ortqvist AK, Dahlgvist E, et al. Association of SARS-CoV-2 Vaccination  
678 During Pregnancy With Pregnancy Outcomes. *JAMA* 2022; **327**(15): 1469-77.
- 679 15. Gonzalez VJ, Li L, Buarbung S, Pahl M, Robinson JF, Gaw SL. Minimal mRNA  
680 uptake and inflammatory response to COVID-19 mRNA vaccine exposure in human  
681 placental explants. *iScience* 2023; **26**(9): 107549.
- 682 16. Africa SS. The Status of women in South Africa: Evidence from selected indicators,  
683 2022.
- 684 17. Delany-Moretlwe S, Lombard C, Baron D, et al. Tenofovir 1% vaginal gel for  
685 prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3,  
686 randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis* 2018; **18**(11):  
687 1241-50.

- 688 18. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili  
689 study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised,  
690 placebo-controlled test-of-concept phase 2b study. *Lancet Infect Dis* 2011; **11**(7): 507-  
691 15.
- 692 19. Pattinson R FS, Gebhardt S, Soma-Pillay P, Niit R, Moodley J. The impact of COVID-  
693 19 on use of maternal and reproductive health services and maternal and perinatal  
694 mortality. *South Afr Health Rev*, 2022.
- 695 20. Moodley Y, Tomita A, de Oliveira T, Tanser F. HIV viral load and pregnancy loss:  
696 results from a population-based cohort study in rural KwaZulu-Natal, South Africa.  
697 *AIDS* 2021; **35**(5): 829-33.
- 698 21. Tukei VJ, Hoffman HJ, Greenberg L, et al. Adverse Pregnancy Outcomes Among HIV-  
699 positive Women in the Era of Universal Antiretroviral Therapy Remain Elevated  
700 Compared With HIV-negative Women. *Pediatr Infect Dis J* 2021; **40**(9): 821-6.
- 701 22. Blencowe H, Cousens S, Jassir FB, et al. National, regional, and worldwide estimates  
702 of stillbirth rates in 2015, with trends from 2000: a systematic analysis. *Lancet Glob*  
703 *Health* 2016; **4**(2): e98-e108.
- 704 23. Tan CS, Collier AY, Yu J, et al. Durability of Heterologous and Homologous COVID-19  
705 Vaccine Boosts. *JAMA Netw Open* 2022; **5**(8): e2226335.
- 706 24. Khoo NKH, Lim JME, Gill US, et al. Differential immunogenicity of homologous versus  
707 heterologous boost in Ad26.COVS.2 vaccine recipients. *Med* 2022; **3**(2): 104-18 e4.
- 708 25. Barouch DH, Stephenson KE, Sadoff J, et al. Durable Humoral and Cellular Immune  
709 Responses 8 Months after Ad26.COVS.2 Vaccination. *N Engl J Med* 2021; **385**(10):  
710 951-3.
- 711 26. Sablerolles RSG, Rietdijk WJR, Goorhuis A, et al. Durability of Immune Responses  
712 After Boosting in Ad26.COVS.2-Primed Healthcare Workers. *Clin Infect Dis* 2023;  
713 **76**(3): e533-e6.

- 714 27. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against  
715 SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-  
716 19/BNT162b2 vaccination. *Nat Med* 2021; **27**(9): 1525-9.
- 717 28. Garrett N, Tapley A, Andriesen J, et al. High Asymptomatic Carriage With the Omicron  
718 Variant in South Africa. *Clin Infect Dis* 2022; **75**(1): e289-e92.
- 719 29. Madhi SA, Kwatra G, Myers JE, et al. Population Immunity and Covid-19 Severity with  
720 Omicron Variant in South Africa. *N Engl J Med* 2022; **386**(14): 1314-26.
- 721

Total  
N=501 230

SHERPA participants  
N=12 342

Sisonke non-SHERPA  
participants  
N=488 888

**N=1094 (8.9%) excluded**

- 473 excluded due to data integrity at 1 site
- 125 could not be linked to their original Sisonke ID
- 142 received >2 Ad26.COVS before mRNA 1273
- 113 received BNT162b2 before mRNA-1273
- 117 received Ad26.COVS after earliest date of mRNA-1273 administration
- 124 Inappropriate enrolment

**N=11 248 (91.1%) included in the analyses**

- 5 102 received Ad26.COVS + mRNA 1273
- 6 146 received Ad26.COVS x 2 + mRNA 1273

**N=75 727 (15.5%) excluded**


- 22 168 received >2 Ad26.COVS
- 48 368 received BNT162b2
- 5 191 received Ad26.COVS after earliest date of mRNA 1273 administration

**N= 413 161 (84.5 %) included in the analyses**

- 185 676 received Ad26.COVS
- 227 485 received Ad26.COVS X2


A

## D614G Neutralization




B

## BA.4 Neutralization




C

## D614G Neutralization - PLWH




D

## D614G Binding




E

## D614G Binding - PLWH




F

## D614G ADCC








G

## D614G ADCC - PLWH



**A**

|                                   | Ad26.COV2.S<br>(1 prior dose) | Ad26.COV2.S<br>(2 prior doses) |
|-----------------------------------|-------------------------------|--------------------------------|
| n                                 | 28                            | 24                             |
| Age (med, IQR)                    | 37 [30-51]                    | 43 [37-47]                     |
| Gender (n, % female)              | 22 (84.6%)                    | 20 (83.3%)                     |
| Days since first dose (med, IQR)  | 344 [335-368]                 | 386 [340-460]                  |
| Days since second dose (med, IQR) | NA                            | 188 [166-209]                  |
| HIV infection (n, %)              | 8 (31%)                       | 8 (33.3%)                      |
| NC seropositive at BL (n, %)      | 23 (88.5%)                    | 19 (79.2%)                     |

**B****C****D****E****F****G**